Scientists hunt for clues in blood to predict cancer treatment success
NCT ID NCT07427186
Summary
This study aims to learn how the immune system responds to immunotherapy drugs given before surgery for early-stage cancers like lung, head and neck, melanoma, and bladder cancer. Researchers will track 600 patients for five years, collecting blood samples to identify biological markers that might predict which patients will benefit most from treatment. The goal is to gather knowledge to help guide future treatment decisions, not to test a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Rangueil
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Larrey
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.